Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety

INTRODUCTION: The intraocular pressure (IOP)-lowering effect and safety of tafluprost 0.0015%/timolol maleate 0.5% combination ophthalmic solution (Taf–TFC) were investigated in a real-world clinical setting. METHODS: A prospective up to 2-year (more than 1 year) observational study has been initiat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ophthalmol Ther
Hlavní autoři: Takagi, Yasutaka, Osaki, Hirotaka, Yamashita, Tomohiro, Kai, Yasuhiko
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5125119/
https://ncbi.nlm.nih.gov/pubmed/27492380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40123-016-0057-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky